Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ProMetic Life Sciences Inc. (OTC: PFSCF).

Full DD Report for PFSCF

You must become a subscriber to view this report.


Recent News from (OTC: PFSCF)

Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH)
Prometic to host Key Opinion Leader meeting on PBI-4050, a novel treatment for Alström Syndrome and promising therapeutic for non alcoholic steatohepatitis (NASH) Canada NewsWire LAVAL, QC, Sept. 5, 2018 LAVAL, QC , Sept. 5, 2018 /CNW Telbec/ -  Prometic Life Sc...
Source: Canada Newswire
Date: September, 05 2018 12:23
ProMetic Life Sciences Inc. 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by ProMetic Life Sciences Inc. in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 15 2018 17:31
ProMetic Life Sciences' (PFSCF) CEO Pierre Laurin on Q2 2018 Results - Earnings Call Transcript
ProMetic Life Sciences Inc. (PFSCF) Q2 2018 Earnings Conference Call August 15, 2018 11:00 AM ET Executives Pierre Laurin – President and Chief Executive Officer Bruce Pritchard – Chief Financial Officer Analysts Dewey Steadman – Canaccord Derren Nathan...
Source: SeekingAlpha
Date: August, 15 2018 17:24
Prometic Reports Second Quarter 2018 Financial Results and Highlights
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and Ryplazim TM  (plasminogen) Submitted plan to FDA regarding filing of the amended BLA for Ryplazim TM  (plasminogen) Q2 revenues of $20.2...
Source: PR Newswire
Date: August, 14 2018 18:07
Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in Journal of Pharmacology and Experimental Therapeutics
PBI-4050 reduces the activation of hepatic stellate cells, the major cells involved in liver fibrosis PBI-4050 decreases liver fibrosis through modulation of the LKB1-AMPK-mTOR pathway AMPK acts as the "master regulator" of cellular energy homeostasis and its role in reducing fibr...
Source: PR Newswire
Date: August, 10 2018 07:15
Prometic to report its second quarter 2018 financial results and hold conference call / webcast
LAVAL, QC , Aug. 7, 2018 /PRNewswire/ -  Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will report its financial results for the second quarter ended June 30, 2018 on Tuesday August 14, 2018 after market close. Prometic will host a...
Source: PR Newswire
Date: August, 07 2018 14:21
Prometic receives Rare Pediatric Disease Designation from U.S. FDA for small molecule drug candidate, PBI-4050
Rare Pediatric Disease Designation granted for the treatment of patients with Alström syndrome Third Rare Pediatric Disease Designation obtained by Prometic LAVAL, QC , Aug. 7, 2018 /PRNewswire/ -   Prometic Life Sciences Inc.  (TSX: PLI) (OTCQX: PFSCF) (" P...
Source: PR Newswire
Date: August, 07 2018 07:00
Prometic conference call to present progress report on AGM corporate action plan
LAVAL, QC , June 22, 2018 /PRNewswire/ -  Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") announced today that it will hold a conference call on Wednesday June 27, 2018 to report on its progress in implementing the updated corporate plan presented during its AGM...
Source: PR Newswire
Date: June, 22 2018 12:38
Prometic Presents New Data on NASH Drug Candidate PBI-4547
New data suggest PBI-4547 offers potential as novel therapy for liver fibrosis, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), diabetes and obesity   New data to be presented at the 2018 American Diabetes Association conference LAVAL, QC , June ...
Source: PR Newswire
Date: June, 22 2018 07:00
FDA Ad Com approaches for PneumRx endobronchial coil
The FDA's Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee will meet on Thursday, June 14, to discuss privately held PneumRx's marketing application seeking approval for its ELEVAIR Endobronchial Coil System for use in emphysema patients to imp...
Source: SeekingAlpha
Date: June, 12 2018 12:27

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.282750.2920.2920.282754,000
2018-12-130.28760.29850.300.2868570,536
2018-12-120.29590.28460.29640.284645,350
2018-12-110.29010.29010.29010.29013,500
2018-12-100.30110.30110.30110.3011285

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-135,02970,5367.1297Cover
2018-12-1230,35045,35066.9239Short
2018-12-113,5003,500100.0000Short
2018-12-10285285100.0000Short
2018-12-0710,10056,70017.8131Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PFSCF.


About ProMetic Life Sciences Inc. (OTC: PFSCF)

Logo for ProMetic Life Sciences Inc. (OTC: PFSCF)

Prometic is an established biopharmaceutical company www.prometic.com with widely recognized expertise in bioseparations, plasma derived therapeutics and small molecule therapeutics development. Prometic offers its bioseparation technologies and expertise for large scale purification of biologics, drug development, proteomics and the elimination of pathogens to industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma to develop and commercialize plasma derived therapeutics. Prometic is also active in developing its own novel small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, targeting, inter alia, the lungs, liver, heart and kidney as well as diabetes, anemia and autoimmune diseases. Headquartered in Laval Canada , Prometic has R amp D facilities in the United Kingdom, the United States and Canada, manufacturing facilities in the UK and Canada and corporate and business development activities in the UK, Canada, USA and Europe. Prometic s common shares trade on the Toronto Stock Exchange TSX under the symbol PLI and the OTCQX International under the symbol PFSCF.

 

Contact Information

 

 

Current Management

  • Pierre Laurin / President, CEO
  • John Moran / CMO
  • Bruce Pritchard / COO, CFO
    • CFO by interim
  • Patrick Sartore / Corporate Secretary, CLO
  • Fred Dumais / IR
  • Simon Best / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Andrew Bishop /
  • Stefan Clulow /
  • Ken Galbraith /
  • David John Jeans /
  • Charles Kenworthy /
  • Pierre Laurin /
  • Louise Menard / Independent Director, Compensation Committee Member, Nominating Committee Member
  • Paul Mesburis / Independent Director, Audit Committee Member, Nominating Committee Member
  • John Moran /
  • Nancy Orr / Independent Director, Audit Committee Member, Compensation Committee Member
  • Bruce Wendel /

Current Share Structure

  • Market Cap: $802,970,398 - 03/15/2018
  • Issue and Outstanding: 710,593,273 - 12/31/2017
  • Float: 691,907,641 - 12/31/2017

 


Recent Filings from (OTC: PFSCF)

Supplemental Information - CFO Certification 2017-Q3
Filing Type: Supplemental Information - CFO Certification 2017-Q3Filing Source: OTC Markets
Filing Date: November, 17 2017
Supplemental Information - CEO Certification 2017-Q3
Filing Type: Supplemental Information - CEO Certification 2017-Q3Filing Source: OTC Markets
Filing Date: November, 17 2017
Interim Financial Report - 2017-Q3
Filing Type: Interim Financial Report - 2017-Q3Filing Source: OTC Markets
Filing Date: November, 17 2017
Management Discussion and Analysis - 2017-Q3
Filing Type: Management Discussion and Analysis - 2017-Q3Filing Source: OTC Markets
Filing Date: November, 17 2017

 

 


Daily Technical Chart for (OTC: PFSCF)

Daily Technical Chart for (OTC: PFSCF)


Stay tuned for daily updates and more on (OTC: PFSCF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PFSCF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PFSCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PFSCF and does not buy, sell, or trade any shares of PFSCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/